Chartwell Investment Partners, LLC Allogene Therapeutics, Inc. Transaction History

Chartwell Investment Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 26, 2022	SELL	$7.65 - $15.29 $243,124 - $485,931	-31,781 Closed	0 $0
Q4 2021 Feb 15, 2022	BUY	$13.13 - $24.52 $143,313 - $267,635	10,915 Added 52.31%	31,781 $474,000
Q2 2021 Jul 19, 2021	BUY	$23.49 - $35.8 $4,416 - $6,730	188 Added 0.91%	20,866 $544,000
Q1 2021 May 03, 2021	SELL	$25.79 - $39.02 $28,626 - $43,312	-1,110 Reduced 5.09%	20,678 $730,000
Q4 2020 Feb 09, 2021	BUY	$25.24 - $43.45 $181,854 - $313,057	7,205 Added 49.41%	21,788 $550,000
Q2 2020 Jul 29, 2020	BUY	$18.39 - $54.04 $268,181 - $788,065	14,583 New	14,583 $624,000

163

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $269M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Chartwell Investment Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Chartwell Investment Partners, LLC with notifications on news.